The U.S. Food and Drug Administration asked manufacturers to remove language about suicidal ideation and behavior from the warnings and precautions sections of several GLP‑1 obesity drug labels following a post‑market review. The agency concluded there is no increased risk of suicidal thoughts or behavior for the approved obesity indications and recommended label changes for products from Eli Lilly and Novo Nordisk. Companies named in the agency requests include Eli Lilly (Zepbound) and Novo Nordisk (Wegovy, Saxenda). The decision follows ongoing pharmacovigilance work and affects how clinicians counsel patients on mental‑health risks during obesity treatment.